Open AccessToxin to medicine and bioisosterism in drug development: a study of the discovery and development of ACE inhibitors from snake venom
Author(s) -
Akolade R. Oladipupo
Publication year - 2020
Publication title -
makedonsko farmacevtski bilten/makedonski farmacevtski bilten
Language(s) - English
Resource type - Journals
eISSN - 1857-8969
pISSN - 1409-8695
DOI - 10.33320/maced.pharm.bull.2020.66.02.003
Subject(s) - drug discovery , drug development , drug , pharmacology , venom , medicine , angiotensin converting enzyme , bioinformatics , chemistry , biology , biochemistry , blood pressure
The advent of the angiotensin-converting enzyme (ACE) inhibitors is a landmark in drug discovery and a breakthrough in the management of hypertension. Their clinical introduction has led to appreciable increase in the lifespan of hypertensive patients. And their development initiated a new era of structure-based or rational drug design that has subsequently been applied successfully for development of drugs for many other disorders. This paper presents an account of the discovery, design and development of ACE inhibitors from an academic perspective and possibly, as a guide to future research. The paper highlights the milestones and recounts the challenges encountered and the strategies applied in the search for ACE inhibitors. This exposition also expounds some of the concepts and intricacies of drug discovery, design and development.Keywords: drug development, ACE inhibitors, snake venom peptide, bioisosterism, antihypertensive agents